Current Neuro-Oncology

Volume 28 Number 18
30 June 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 18, 30 June

Choi M, Choi Y, Lee J, Jeong SY, Kim M, Hwang I, Park JE, Park YW, Choi SH, Choi KS.
Distinguishing Molecular and Histologic Glioblastomas Using Multiparametric MRI-Based Habitat Analysis.
Korean J Radiol. 2026 Jun 23;27(7):670-681. doi: 10.3348/kjr.2025.1969. PMID: 42388098. ˍ

Hong B, Chaib H, Moros G, Tsoy Y, Ziegler S, Heissler HE, Mawrin C, Shiban E.
Impact of weak MGMT promoter methylation on the prognosis of patients with newly diagnosed glioblastoma.
J Neurosurg Sci. 2026 Jun 23. doi: 10.23736/S0390-5616.26.06772-X. PMID: 42334248˰ ˍ

Scheer M, Prell J, Mawrin C, Leisz S, Schob S, Rampp S, Simmermacher S.
Not all enhancing lesions are tumor recurrence: Foreign body granulomas after glioma resection.
Brain Spine. 2026 Jun 23;6:106140. doi: 10.1016/j.bas.2026.106140. PMID: 42382657. ˍ

Ozer BH, Lindhorst SM, Merrell RT, Trevino CR, Rudnick JD, Avgeropoulos NG, Ramakrishna N, Khagi S, Rauf Y, Walbert T, Pan E, Youssef M, Fink KL, Mandel JJ, Taylor LP, Colman H, Dunbar EM, Paleologos N, Burton EC, Wu J, Leeper HE, Gonzalez J, Penas-Prado M, Raizer JJ, Veglia E, Craig S, Yuan Y, Chambers C, Wall K, Grajkowska E, Mendoza T, Armstrong TS, Gilbert MR.
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
medRxiv [Preprint]. 2026 Jun 24:2026.06.22.26354817. doi: 10.64898/2026.06.22.26354817. PMID: 42396282. Trial registration ID: NCT03018288. ˍ

Wu B, Zhang Z, Ma H, Huang J, Liu X, Shi L, Dong X, Lei D, Wang X, Zhang F, Zhao H, Lin H, Fu R, Zou Z, Qin Y, Wang H, Hu X, Yao D, Yang L, Yang J, Hong X, Wang J, Wen L, Zhang C, Liang Z, Yang Z, Nie X, Liu G, Hu F, Peng G, Jiang X, Yang K.
Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O⁶-methylguanine-DNA methyltransferase glioblastoma: A single-arm, phase 2 study.
Cancer. 2026 Jun 24;132(13):e70502. doi: 10.1002/cncr.70502. PMID: 42339996. Trial registration ID: ChiCTR2000040116. ˍ

Anghileri E, Marcassoli A, Villani V, Didato G, Milanaccio C, Pasini E, Bennicelli E, Persico P, Bini P, Berzero G, Mastronuzzi A, Filippi M, De Palma L, Arcara G, Bellini A, Maschio M, Pace A, Farinotti M, Silvani A; National Virtual Institute of Italian Network of Neuroscience.
Mapping integrated care for brain tumour-related epilepsy in the Italian RIN-IRCCS network.
Neurol Sci. 2026 Jun 26;47(7):589. doi: 10.1007/s10072-026-09188-w. PMID: 42350833. ˍ

Li J, Hou L, Zhou H, Zhang Z, Wang Y, Zhan X, Wang W, Tian L, Xue X.
Postoperative clinical prognosis in 160 cases of glioblastoma and efficacy of vascular targeted therapy for recurrence.
Neoplasma. 2026 Jun 26:260306N56. doi: 10.4149/neo_2026_260306N56. PMID: 42429148. ˍ

*Giordano FA, Ganslandt O, Münter MW, Combs SE, Diehl C, Meyer B, Herrlinger U, Schneider M, Kahl KH, Shiban E, Goenka A, Schulder M, Lucas A, Plans G, Brehmer S, Ruder AM, García-Cabezas S, Solivera J, Cifarelli CP, Wenz F, Sarria GR, Pope WB, Layer JP, Tsien CI, Petrecca K; INTRAGO-II Study Group.
Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial.
Lancet Oncol. 2026 Jun 29;27(7):864-878. doi: 10.1016/S1470-2045(26)00235-4. PMID: 42372746. Trial registration ID: NCT02685605. ˍ

Ng IB, Jani RH, Goyal A, Pickles A, Prabhu VC, Wainwright DA, Barton K, Thakkar JP.
Single Institution Retrospective Study to Determine Time to First True Progression in MGMT-Methylated Glioblastoma Patients Who Received Standard of Care.
J Clin Med. 2026 Jun 29;15(13):5073. doi: 10.3390/jcm15135073. PMID: 42452534. ˍ

Gomez S, DiCioccio RA, Geiger AE, Grant ML, Reynolds E, Datar A, McCann CD, Tanna J, Kukadiya D, Hoq F, Zhang A, Hanley PJ, Webb JL, Kilburn LB, Rood BR, Fonseca A, Meany HJ, Vézina LG, Packer RJ, Cruz CRY, Bollard CM, Hwang EI.
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.
Nat Med. 2026 Jun 30. doi: 10.1038/s41591-026-04449-9. PMID: 42380677. Trial registration ID: NCT03652545. ˍ

Li W, Jiang S, Liu K, Li Z, Yang J, Liu W, Huang Y, Yang M, Guo S, Ruan S.
Exosome Secretion Drives Chemo-Resistance of Temozolomide in Glioblastoma.
J Extracell Biol. 2026 Jun 30;5(7):e70161. doi: 10.1002/jex2.70161. PMID: 42383157. ˍ

Lindsay HB, Billups CA, Kocak M, Alban TJ, Young Poussaint T, Wong P, Chan TA, Kovacic B, Makarov V, Juric I, Diaz-Montero CM, Srivastava R, Pavicic P, Parthasarathy P, Lenzen A, MacDonald TJ, Pollack IF, Vinitsky A, Robison NJ, Baxter P, Hwang EI, Leggas M, Khalil DN, Fangusaro J, Onar-Thomas A, Dunkel IJ.
Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.
Clin Cancer Res. 2026 Jun 30. doi: 10.1158/1078-0432.CCR-26-0655. PMID: 42377093. Trial registration ID: NCT03389802˰ ˍ

Zhang L, Wang H, Huang G, Qi X, Carcaboso AM, Wang C, Feng J, Han S, Cheng Z, Ma Z, Yang Y, Xu H, Chen M, Li Y, Zhang X, Cui G, Lyu J, Duan Z, Xu A, Yan C.
The clinical and molecular landscape of thalamic glioma.
Neuro Oncol. 2026 Jun 30:noag146. doi: 10.1093/neuonc/noag146. PMID: 42377275. ˍ